Menu
Back to Journals » Drug Design, Development and Therapy » Volume 10
Molecular mechanisms of cisplatin resistance in cervical cancer
Authors Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X
Received 14 February 2016
Accepted for publication 10 March 2016
Published 7 June 2016 Volume 2016:10 Pages 1885—1895
DOI https://doi.org/10.2147/DDDT.S106412
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Ankur Sharma
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Wei Duan
Haiyan Zhu, Hui Luo, Wenwen Zhang, Zhaojun Shen, Xiaoli Hu, Xueqiong Zhu
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of China
Abstract: Patients with advanced or recurrent cervical cancer have poor prognosis, and their 1-year survival is only 10%–20%. Chemotherapy is considered as the standard treatment for patients with advanced or recurrent cervical cancer, and cisplatin appears to treat the disease effectively. However, resistance to cisplatin may develop, thus substantially compromising the efficacy of cisplatin to treat advanced or recurrent cervical cancer. In this article, we systematically review the recent literature and summarize the recent advances in our understanding of the molecular mechanisms underlying cisplatin resistance in cervical cancer.
Keywords: cisplatin, epithelial–mesenchymal transition, microRNA, molecular mechanism, resistance
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.